DelveInsight’s “Acne Vulgaris Market Insights, Epidemiology, and Market Forecast- 2032” report delivers an in-depth understanding of the Acne Vulgaris, historical and forecasted epidemiology as well as the Acne Vulgaris market trends in the United States, EU4 (Germany, Spain, Italy, France), and the United Kingdom, and Japan.

 

Key Takeaways from the Acne Vulgaris Market Research Report

• Multiple new drugs are going through different phases of clinical trials; these upcoming therapies are expected to increase the Acne Vulgaris market size in the coming years.
• As per the study conducted by Mambrin et al. (2018), females are predominantly affected compared to males.
• As per Mambrin et al. (2018), acne in females is more prevalent than in male patients. The evaluation of acne severity has showed that “mild acne” is the most frequent form.
• The leading Acne Vulgaris Companies working in the market include Galderma SA, Bausch Health Companies Inc, GSK plc, AbbVie Inc, Sun Pharmaceutical Industries Ltd, Cosmo Pharmaceuticals NV, DermResearch Inc, Maruho Co Ltd, TKL Research Inc, Bayer AG, and others.
• Promising Acne Vulgaris Pipeline Therapies in the various stages of development include S6G5T-3, 50 mg P005672-HCl, Tazarotene, Tazaroc Gel, AKLIEF®, Sarecycline, SB204 4%, and others.
• March 2024: Menning Labs- This twelve-week trial will examine the effectiveness of a Menning Labs EQ Product Line acne product. Participants will use the exfoliating cleanser, cream, and gel daily for 8 weeks. Participants will complete questionnaires at Baseline, Day 1, Day 3, Day 7, Day 28, Day 42, and Day 56. Participants will also provide before-and-after photos at Baseline, Day 7, and Day 42, as well as undergo expert skin grading at Baseline and Day 42. The questionnaire on Day 56 will mark the conclusion of the trial.
• February 2024: Biofrontera Bioscience GmbH announced a study of Phase 2 clinical trials for 1h Incubation Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT). The aim of this study is to test the safety and efficacy of photodynamic therapy (PDT) for the medication Ameluz® performed with the PDT-lamp BF-RhodoLED® in comparison to the respective placebo treatment for moderate to severe Acne vulgaris.

 

Discover which therapies are expected to grab the Acne Vulgaris Market Share @ Acne Vulgaris Market Outlook Report

 

Acne Vulgaris Overview

Acne vulgaris is an inflammatory disorder of pilosebaceous unit, which runs a chronic course and it is self-limiting. Acne vulgaris is triggered by propionibacterium acnes in adolescence, under the influence of normal circulating dehydroepiandrosterone. Acne vulgaris is triggered by Cutibacterium acnes in adolescence, under the influence of normal circulating dehydroepiandrosterone (DHEA). It is a very common skin disorder which can present with inflammatory and non-inflammatory lesions chiefly on the face but can also occur on the upper arms, trunk, and back.

 

Acne Vulgaris Epidemiology Insights

The epidemiology section of Acne Vulgaris offers insights into both historical and current patient populations, as well as forecasted trends across seven major countries. This section aids in understanding the factors behind present and projected trends through analysis of various studies and input from key opinion leaders. Additionally, this portion of the market report provides information on the diagnosed patient pool, trends, and underlying assumptions. Acne Vulgaris epidemiology segmentation is given below:-

• Total Acne Vulgaris Prevalent Cases
• Acne Vulgaris Severity-specific Diagnosed Prevalent Cases
• Acne Vulgaris Gender-specific Diagnosed Prevalent Cases
• Acne Vulgaris Diagnosed and Treatable Cases

 

Download the report to understand which factors are driving Acne Vulgaris Epidemiology trends @ Acne Vulgaris Epidemiological Insights

 

Acne Vulgaris Drugs Market

The Acne Vulgaris Drugs Market is expected to witness substantial growth in the coming years as more targeted therapies receive regulatory approval and enter clinical practice. Additionally, ongoing research efforts aimed at better understanding the molecular mechanisms underlying Acne Vulgaris signaling in Acne Vulgaris are likely to uncover new therapeutic targets and further expand treatment options for patients.

 

Acne Vulgaris Treatment Market Landscape

The Acne Vulgaris treatment market landscape has witnessed significant advancements over the past years, with targeted therapies playing a crucial role in improving outcomes for patients. Among these targeted therapies, the emergence of Acne Vulgaris has garnered attention in the medical community, presenting both challenges and opportunities in treatment strategies.

 

To know more about Acne Vulgaris treatment guidelines, visit @ Acne Vulgaris Treatment Market Landscape

 

Acne Vulgaris Market Outlook

The report’s outlook on the Acne Vulgaris market aids in developing a comprehensive understanding of historical, current, and projected trends. This is achieved by examining the influence of existing Acne Vulgaris therapies, unmet needs, as well as drivers, barriers, and the demand for advanced technology. This section provides detailed insights into the trends of each marketed Acne Vulgaris drug and late-stage pipeline therapy. It assesses their impact based on various factors such as annual therapy costs, inclusion/exclusion criteria, mechanism of action, compliance rates, market demand, patient population growth, covered patient segments, anticipated launch year, competition with other therapies, brand value, and input from key opinion leaders. The analyzed Acne Vulgaris market data are presented concisely through relevant tables and graphs to offer a clear overview of the market dynamics.

 

Acne Vulgaris Drugs Uptake

• BioPharmX is developing a novel, proprietary topical minocycline gel formulation (BPX-01) for the treatment of acne vulgaris. The product is the first candidate from companies’ anhydrous hydrophilic topical delivery system and in their formulation, the minocycline is completely solubilized. BPX-01 utilizes minocycline that is solubilized and stable in a vehicle that is hydrophilic and capable of penetrating into the region of the skin where P. acnes reside. 

• GT20029, being developed by Kintor Pharmaceuticals, completed its Phase I in the US (and China). This drug is a topical gel and has recently shown to be well tolerated, safe with good pharmacokinetic characteristics in the subjects. This is the first topical PROTAC compound which has completed Phase I. Positive topline data has been released by the company in February 2023. 

• KX-826 is an additional drug which is being developed by Kintor Pharmaceuticals, for Acne vulgaris that just completed its preclinical phase in the US. This agent targets mild to moderate patients and is being developed in topical formulation. Company is looking forward to next step of filing IND to initiate clinical development of the drug. 

• Botanix Pharmaceuticals is developing BTX 1503, is a new topical treatment for moderate to severe acne, which utilizes synthetic cannabidiol as the drug active, together with Botanix’s proprietary Permetrex drug delivery technology. The company has already published Phase II results and planning for Phase III trial.

 

Major Acne Vulgaris Companies

Several Acne Vulgaris Companies working in the market include Galderma SA, Bausch Health Companies Inc, GSK plc, AbbVie Inc, Sun Pharmaceutical Industries Ltd, Cosmo Pharmaceuticals NV, DermResearch Inc, Maruho Co Ltd, TKL Research Inc, Bayer AG, and others.

 

Learn more about the FDA-approved drugs for Acne Vulgaris @ Drugs for Acne Vulgaris Treatment

 

Scope of the Acne Vulgaris Market Research Report

• Coverage- 7MM
• Acne Vulgaris Companies- Galderma SA, Bausch Health Companies Inc, GSK plc, AbbVie Inc, Sun Pharmaceutical Industries Ltd, Cosmo Pharmaceuticals NV, DermResearch Inc, Maruho Co Ltd, TKL Research Inc, Bayer AG, and others.
• Acne Vulgaris Pipeline Therapies- S6G5T-3, 50 mg P005672-HCl, Tazarotene, Tazaroc Gel, AKLIEF®, Sarecycline, SB204 4%, and others.
• Acne Vulgaris Market Dynamics: Acne Vulgaris Market Drivers and Barriers
• Acne Vulgaris Market Access and Reimbursement, Unmet Needs and Future Perspectives

 

Discover more about Acne Vulgaris Drugs in development @ Acne Vulgaris Clinical Trials Assessment

 

Table of Content

1. Report Introduction

2. Acne Vulgaris Executive Summary

3. Acne Vulgaris Market Share at a glance

4. Acne Vulgaris Market Disease Background and Overview

5. Patient Journey

6. Acne Vulgaris Epidemiology and Patient Population

7. Country Wise: Acne Vulgaris Epidemiology

8. Current Acne Vulgaris Treatment and Medical Practices

9. Acne Vulgaris Marketed Drugs

10. Acne Vulgaris Emerging Therapeutics

11. Acne Vulgaris Market Size

12. Region-Wise Acne Vulgaris Market Size

13. Acne Vulgaris KOL Views

14. Acne Vulgaris SWOT Analysis

15. Acne Vulgaris Unmet Needs

16. Reimbursement and Acne Vulgaris Market Access

17. Appendix

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/medical-marijuana-market-insight